Business Context and Reporting Period
This Form 8-K is a current report filed by NanoVibronix, Inc. (trading symbol: NAOV) on October 11, 2021. The registrant is incorporated in Delaware and operates on the Nasdaq Capital Market. The filing serves as a Regulation FD disclosure regarding a press release issued on August 17, 2021, which announced new clinical data for the company's PainShield product.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on the disclosure of non-financial material information regarding product development.
Material Changes
The material change disclosed is the release of new study data concerning the PainShield product. The company attached the relevant press release as Exhibit 99.1 to this filing. No financial or operational changes compared to prior periods are detailed in this specific document.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or a discussion of risks and contingencies beyond the context of the product data announcement. The document incorporates the August 17, 2021 press release by reference for details on the study results.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 17, 2021) for specific details on the PainShield study data.
- Verify the company's current financial status through its most recent 10-Q or 10-K filing, as this 8-K contains no financial statements.
- Confirm the trading status of NAOV on the Nasdaq Capital Market.
- Note the discrepancy between the metadata company name ("Envue Medical, Inc.") and the actual registrant in the text ("NanoVibronix, Inc."); the filing pertains to NanoVibronix.